32.jpg)
56.jpg)
RUTHENIUM COMPLEXES FOR TREATING CANCER WHICH COMPRISES CANCER STEM CELLS
US2020054647
The present invention relates to the use of ruthenium(II) complexes for preparing a medicinal product for treating cancer, particularly cancer comprising cancer stem cells. Said ruthenium complexes are capable of selectively metallating guanine quadruplexes, thus resulting in increased expression of the c-MYC oncogene. This increase in the proportion of c-MYC may promote the differentiation of cancer stem cells.
IGN -111 is a synthetic, ruthenium-containing complex (small molecule), that targets and eliminates CSC populations (CSCs) in primary human adenocarcinoma cells demonstrating high selectivity and low toxicity. This potential treatment is also effective to remove hybrid non-CSC that could potentially repopulate the CSCs pool. IGN -111 is currently under development for pancreatic ductal adenocarcinoma and colorectal cancer. Moreover, this treatment could also be effective in any type of tumour whose tumorigenesis is based on CSCs.